NCT06533826 - TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd | Biotech Hunter

Enrollment

357

Participants

Timeline

Start Date

October 29, 2024

Primary Completion Date

January 1, 2028

Study Completion Date

August 1, 2038

Conditions

Breast CancerHER2-low Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer

Interventions

DRUG

Trastuzumab Deruxtecan

A HER2-directed ADC, 100mg/vial, via intravenous (into the vein) infusion per protocol.

DRUG

Datopotamab Deruxtecan

A TROP2-directed antibody drug conjugate, 100mg/vial, via intravenous (into the vein) infusion per protocol.

Trial Locations (9)

RECRUITING

Montefiore Einstein Comprehensive Cancer Center, The Bronx

RECRUITING

Georgetown University Medical Center, Washington D.C.

RECRUITING

University of North Carolina, Chapel Hill

RECRUITING

Vanderbilt Cancer Center, Nashville

RECRUITING

University of Chicago Medical Center, Chicago

RECRUITING

Baylor College of Medicine, Houston

RECRUITING

Yale University Cancer Center, New Haven

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston